ZUG, Switzerland, April 04, 2024 Pharvaris , a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema attacks,.
Pharvaris N.V. announced the presentation of one oral session and two posters at the Global Allergy and Asthma Excellence Network Urticaria Centers of Reference and Excellence Conference, being held.